RxDoctor Payments Data

Abid Bashir, MD

Nephrology · Athens, GANPI 1700822608

Payments from drug & device makers

$2,685in general payments, 2019–2025

Across 151 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$662
  • Otsuka America Pharmaceutical, Inc.$215
  • AstraZeneca$213
  • Fresenius USA Marketing, Inc.$208
  • Bayer$193
  • Novartis$130
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,40690%
  • Education$27910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,685 in reported general payments places this provider in the 55th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$271,275
Medicare patients
366
Services billed
1,740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide86$287,382
FarxigaDapagliflozin Propanediol64$51,923
JardianceEmpagliflozin42$39,567
KerendiaFinerenone26$33,240
Cinacalcet Hcl95$26,796
Sevelamer Carbonate151$23,519
JanuviaSitagliptin Phosphate22$20,521
EliquisApixaban14$10,347
LokelmaSodium Zirconium Cyclosilicate13$7,456
Nifedipine ErNifedipine132$3,995
Calcitriol244$3,303
Midodrine Hcl35$2,473
Doxazosin Mesylate186$2,245
Hydralazine Hcl181$2,169
Torsemide103$2,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$208$287,38286 claims
AstraZenecaFarxiga, Lokelma$213$59,37977 claims
Boehringer IngelheimJardiance$123$39,56742 claims
BayerKerendia$193$33,24026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 388 nephrology providers in Georgia.

Other nephrology in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →